Business Description
Abbisko Cayman Ltd
ISIN : KYG0028A1085
Total Employee Number:
276Compare
Compare
Traded in other countries / regions
02256.Hong Kong8ZD.Germany IPO Date
2021-10-13Description
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.92 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | 2.2 | |||||
Interest Coverage | 11.71 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 8.57 | |||||
Beneish M-Score | -1.35 | |||||
WACC vs ROIC | ||||||
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.92 | |||||
9-Day RSI | 49.02 | |||||
14-Day RSI | 50.2 | |||||
3-1 Month Momentum % | -3.96 | |||||
6-1 Month Momentum % | -17.04 | |||||
12-1 Month Momentum % | -31.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.98 | |||||
Quick Ratio | 4.98 | |||||
Cash Ratio | 4.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | -1.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 6.43 | |||||
Net Margin % | 8.55 | |||||
EBITDA Margin % | 22.76 | |||||
FCF Margin % | 11.65 | |||||
OCF Margin % | 12.56 | |||||
ROE % | 2.58 | |||||
ROA % | 2.28 | |||||
ROIC % | 6.91 | |||||
3-Year ROIIC % | 118.18 | |||||
ROC (Joel Greenblatt) % | 280.39 | |||||
ROCE % | 5.74 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 148.45 | |||||
Forward PE Ratio | 146.5 | |||||
PE Ratio without NRI | 155 | |||||
Price-to-Owner-Earnings | 110.95 | |||||
PS Ratio | 10.07 | |||||
PB Ratio | 3.29 | |||||
Price-to-Tangible-Book | 3.3 | |||||
Price-to-Free-Cash-Flow | 85.69 | |||||
Price-to-Operating-Cash-Flow | 79.25 | |||||
EV-to-EBIT | 42.86 | |||||
EV-to-EBITDA | 35.96 | |||||
EV-to-Revenue | 8.19 | |||||
EV-to-FCF | 70.25 | |||||
Price-to-GF-Value | 0.86 | |||||
Price-to-Graham-Number | 4.77 | |||||
| Price-to-Net-Current-Asset-Value | 3.72 | |||||
| Price-to-Net-Cash | 3.79 | |||||
Earnings Yield (Greenblatt) % | 2.33 | |||||
FCF Yield % | 1.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abbisko Cayman Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 669.082 | ||
| EPS (TTM) (HK$) | 0.071 | ||
| Beta | 1.1417 | ||
| 3-Year Sharpe Ratio | 0.88 | ||
| 3-Year Sortino Ratio | 1.72 | ||
| Volatility % | 73.69 | ||
| 14-Day RSI | 50.2 | ||
| 14-Day ATR (HK$) | 0.62368 | ||
| 20-Day SMA (HK$) | 10.47525 | ||
| 12-1 Month Momentum % | -31.05 | ||
| 52-Week Range (HK$) | 8.34 - 19.78 | ||
| Shares Outstanding (Mil) | 717.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abbisko Cayman Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abbisko Cayman Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abbisko Cayman Ltd Frequently Asked Questions
What is Abbisko Cayman Ltd(HKSE:02256)'s stock price today?
The current price of HKSE:02256 is HK$10.54. The 52 week high of HKSE:02256 is HK$19.78 and 52 week low is HK$8.34.
When is next earnings date of Abbisko Cayman Ltd(HKSE:02256)?
The next earnings date of Abbisko Cayman Ltd(HKSE:02256) is .
Does Abbisko Cayman Ltd(HKSE:02256) pay dividends? If so, how much?
Abbisko Cayman Ltd(HKSE:02256) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Abbisko Therapeutics Deepens R&D Collaboration with Lilly | 2026-06-23 | ||
| Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC | 2024-09-18 |
Articles on Abbisko Cayman Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers